Pfizer to buy cancer drug developer Trillium in $3.1b deal
Trillium’s two lead molecules, TTI-622 and TTI-621, block signalling proteins involved in blood cancers, and are both in human trials across several types of disease.
from Sydney Morning Herald - Latest News Read More
No comments:
Post a Comment
Thank You for sharing your views. I hope you like the arts posted.
No comments:
Post a Comment
Thank You for sharing your views. I hope you like the arts posted.